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Abslraer: Two polyhydroxylated quinolizidincs, (lR,2R,3R,9S,9aR>1,2,3,9-teaahydroxyquinolizidine 9 and 
(1R,2R,33R,9R,9aYJ-1,2,3,9-tetrabydroxyquinolizidine 10, have been synthesized by the reductive double cycliiation 
of 1% and 15fS. Quinolizidine 9 can be viewed either as a ring expanded analog of 6-epicastanospermine or of 8- 
episwainsonine, while 10 is a ring expanded analog of 1,6,8a-triepicastanospzmhe or of zla-episwainsonine. 
Polyhydroxylated alkaloids such as castanospermine 1, swainsonine 2, deoxynojirimycin 3, 
deoxymannojirimycin 4, alexine 5, and their derivatives have attracted considerable interest in recent years 
due to their potent activity as glycosidase inhibitors. 1 Further interest in this class of compounds has been 
generated by their wide range of pharmacological activity, including anti-viral, anti-HIV, anti-cancer, anti- 
feedant, and immunomgulatory activity.lv2v3 
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Considerable effort has been put forth by a number of researchers to investigate the structure-activity 
relationships of the polyhydroxylated indolizidines, resulting in the synthesis of many of the stereoisomers of 
castanospermine 1 and swainsonine 2 for biological evaluation. 2.3 Stereoisomers of polyhydroxylated 
pyrrolizidines (e.g. alexine 5 and australine) as well as ring contracted versions of polyhydroxylated 
indolizidine alkaloids have also been prepared and in some cases evaluated for inhibitory activity.4 Few 
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reports of ring expanded analogs of polyhydroxylated indolizidines have appeared. Grandig and Sttitz et al 
prepared the castanospermine homologue (lR,2R,3S,9S,9aR)-1,2,3.9-tetrahydroxyquinolizidine 7, which has 
shown g-glucosidase inhibitory activity.5 Liu et al prepared the hydroxymethyl substituted quinolizidine 8, 
which strongly inhibits a-glucosidase I from pig kidney. 6 To further explore the chemistry of this family of 
compounds we have undertaken the synthesis the polyhydroxylated quinolizidines 9 and 10. Compound 9 
closely resembles D-mannopyranose. It can be viewed as a ring expanded analog of the naturally occuring 
amyloglucosidase inhibitor 6epi-castanopermine 8,3 or as a hydroxymethine ring expanded version of I-epi- 









6Epicastanospermine a-t2 8-Episwainsonine 
1,6,8a-Triepicastanospetmine la-Episwainsonine 
The key step in the synthesis of 9 and 10 is the efficient formation of the quinolizidine ring system via 
a reductive double alkylation of an azido-epoxide that possesses an o-leaving group (Scheme 1). We&l7 and 
others4avd*8 have previously employed a similar strategy to assemble pyrrolizidine and indolizidine ring 
systems. 
Scheme 1 
Our synthesis began with 2,3,4-tri-O-benzyl-D-arabinopyranose 11, which was prepared from 
D-arabinose in three steps according to Fletcher’s procedure (Scheme 2).9 Wittig olelination of 11 with the 
chloro-substituted phosphonium salt 1210 selectively yielded the (Z)-chloroalkenoll3 in 7 1% yield, which was 
then converted to azide 14 in 84% yield using the Mitsunobu method.11 Epoxidation of 14 with m-CPBA 
produced an inseparable mixture of epoxides 15a and 158 (2.5 : 1) in 88% (a and 8 refer to the orientation of 
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the epoxide oxygen). Reduction of the mixture of azido-epoxides 15cdlSp to amino-epoxides 16crI16p without 
debenzylation was accomplished under mild Pd-catalyzed hydrogenolysis conditions. The amino compounds 
16cz/16f~ were not purified, but were heated in refluxing ethanol containing K2CO3 to produce a mixture of 
quinolizidines 17 and 18 (2.5 : 1) in 65% from 15a/lSg. Compounds 17 and 18 separated (Siti) and their 
stereochemistries were assigned by examination of rH NMR coupling constants.12 The stereochemistry of the 
major isomer 17 implies that 15~ is the major product of the epoxidation reaction. Debenzylation of 17 and 18 
was carried out under more rigorous Pd-catalyzed hydrogenolysis conditions to yield respectively 
(lRJR,3R,9S.9aR)-1,2,3,9-tetrahydroxyquinolizidine 9 in 99% and (lR,2R,3R,9R, 9aS)-1,2,3,9-tetrahydroxy- 
quinolizidine 10 in 92%.13 





14 (84%) 15a + 15s 160! + 16p 
(2.51, 88%) J 
BnO OH 
;;y& + 111% EgtY.igg;;i;; 
.., . 
17 (2.51, 65%) l8 eq. PPh3 in PhH, add 1.2 eq. HNs as a 
I I 1.2M soln in PhH, cool to 0 ‘C, add 
e e 1.2 eq. DEAD dropwise, warm to r.t. for 
30 min. (c) 2 eq. m-CPBA, CHaCla, 
0 ‘C, then warm to r.t. for 12h. (d) 10% 
w/w of 10% Pd/C, EtzO/EtOH (2:1), Hz 
(1 atm), r.t. for 24h; filter off Pd/C, then 
6 eq. KaC@, EtOH, reflux, 24h. Separate 
diastereomers. (e) 45% w/w of 10% Pd/C, 
2% HCl in MeOH, Hz (45 psi), r.t., 48h. 
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The two isomers can be differentiated by the 1H coupling constants between H9-H9a, Hl-H9a and Hl- 
H2. Neither isomer shows an axial-axial coupling between H9-H9a indicating that these hydrogens are 
cis and that H9 is equatorial in both structures. The major isomer 17 shows axial-axial coupling between 
both Hl-H9a and Hl-H2 (Jt,9== Jt,2 = 9.5 Hz), while the minor isomer 18 shows an axial-equatorial 
coupling between Hl-H9a (Jt,9a= 2.4 Hz), and an equatorial-equatorial coupling between Hl-H2, (51,2= 
3.4 Hz). 
Representative spectral data: 9: tH NMR (D20,300 MHz) 63.98 (broad s, lH), 3.79 (broad s, lH), 
3.61 (t, J = 9.8 HZ, lH), 3.32 (dd, J= 3.5.9.8 Hz, lH), 2.72 (dd, J= 2.9, 13.0 Hz, lH), 2.65 (broad d, J 
= 11.5 Hz, lH), 2.16 (d, J= 12.9 Hz, lH), 1.94 (broad t, J= 11.5 Hz, lH), 1.6-1.8 (m, 3H), 1.25-1.45 
(m. 2H). t3C NMR (D20, CM313 ext std. 90 MHz, JMOD) 674.44 (+), 67.99 (+), 67.77 (+), 67.21 (+), 
58.92 (-), 54.85 (-), 29.87 (-), 18.48 (-). 10: tH NMR (D20. 300 MHz) 63.98 (d, J =1.6 Hz, lH), 3.93 
(ddd, J= 3.2,4.9, 11.6 HZ, lH), 3.88 (dd, J= 1.8, 3.7 HZ, lH), 3.70 (t. J= 3.3 Hz, lH), 2.66 (broad d, J 
= 11.6 Hz, lH), 2.49 (dd, J = 4.9, 10.9 Hz, lH), 2.12 (t, J =11.2 Hz, lH), 2.09 (broad s, lH), 1.98 (m. 
IH), 1.71 (dt, J= 3.7, 12.8 Hz, lH), 1.62 (broad d, J= 13.9 Hz, lH), 1.41 (ddd, J= 2.5,3.0, 13.5 Hz, 
lH), 1.31 (m, 1H). t3C NMR (D20, CDC13 ext std. 90 MHz) 676.72,72.84,72.02,67.35,61.86,58.42, 
57.43,33.78,21.24. 
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